

VICURON PHARMACEUTICALS INC  
Form 8-K  
May 28, 2004

---

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, D.C. 20549**

---

**FORM 8-K**

---

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**  
**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported):**

**May 24, 2004**

---

**Vicuron Pharmaceuticals Inc.**

**(Exact Name of Registrant As Specified in its Charter)**

---

**Delaware**  
**(State or Other Jurisdiction**  
  
**of Incorporation)**

**000-31145**  
**(Commission File Number)**

**04-3278032**  
**(I.R.S. Employer**  
  
**Identification Number)**

**455 South Gulph Road, Suite 305, King of Prussia, PA 19406**

**(Address of Principal Executive Offices) (Zip Code)**

**(610) 205-2300**

**(Registrant's telephone number, including area code)**

**not applicable**

**(Former Name or Former Address, if Changed Since Last Report.)**

---

**Item 5. Other Events.**

On May 24, 2004, Vicuron Pharmaceuticals Inc. announced that it received an approvable letter from the U.S. Food and Drug Administration. However, the letter indicated that Vicuron's New Drug Application submission for anidulafungin does not currently support a labeling claim for the initial treatment of esophageal candidiasis.

A copy of the press release relating to such announcement is attached to this Current Report on Form 8-K as Exhibit 99.1

**Item 7. Financial Statements, Pro Forma Financial Information and Exhibits.**

(c) Exhibits.

See Exhibit Index attached hereto.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

VICURON PHARMACEUTICALS INC.  
(Registrant)

Date: May 27, 2004

By: /s/ George F. Horner III

---

George F. Horner III  
President and Chief Executive Officer

**EXHIBIT INDEX**

Pursuant to Item 601(a)(2) of Regulation S-K, this Exhibit Index immediately precedes the exhibit.

<b><u>Exhibit No.</u></b>	<b><u>Description</u></b>
99.1	Press release of Vicuron Pharmaceuticals Inc. dated May 24, 2004.